Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034Martin J. van den Bent, Denis Lacombe, A.A. Brandes et al.|Journal of Clinical Oncology|2007Cited by 53
2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034)Martin J. van den Bent, T. Gorlia, Denis Lacombe et al.|European Journal of Cancer Supplements|2007Cited by 5
Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancerPierFranco Conte, Valentina Guarneri, Michele Aieta et al.|Annals of Oncology|2017Cited by 4